Genetesis

A note of congratulations to?PI Dr. Abhiram Prasad, Dr. Claire Raphael,?and the rest of the MICRO2 study team at Mayo Clinic on enrolling their first MICRO2 patient! With this latest installation of CardioFlux MCG at Mayo Clinic, our team is proud to share that our entire extended network of MICRO2 enrolling sites is fully activated and actively enrolling. Early evidence suggests that MCG may have a unique ability to help physicians diagnose CMD instantly and non-invasively, something that is not always true under the current standard of care. MICRO2 has been designed to test whether or not this hypothesis is true, with an eye on a potential De Novo application to the FDA next year. In conducting MICRO2, our team has been incredibly fortunate to partner with many of cardiology's foremost leaders in CMD research and care. Mayo Clinic is certainly no exception to that rule! Welcome aboard to?Drs. Prasad and Raphael?and the rest of their supporting team as we explore this new opportunity to make a significant dent into the problem of CMD. #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congratulations to?PI Dr. Ankitkumar Patel, and his colleagues at Mountainside Medical Center, including?Valerie Allusson, Valarie McPherson, Joshua Jerome, Taneya Williams-Lewis, Alyssa A. Stolarik, Eugenio Hernandez, Stephanie Fabian, and Tim O'Brien,?on the enrollment of their facility's first patient in MICRO2! Despite extensive research across many years, the importance of coronary microvascular dysfunction (CMD) continues to be underrecognized and underappreciated in the current standard of care, all of this despite the fact that CMD has been correlated with a significantly increased risk of major adverse cardiac events (MACE) as well as overall mortality. Our team's hope is that an easier, faster, more accessible diagnostic option for CMD might change this trend and drive awareness around the importance of proper functional interrogation of a patient's potential ischemia. We're looking forward to continuing to collaborate with Dr. Patel and his team as we continue making progress on MICRO2! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congrats to?PI Dr. Odayme Quesada, Susan Reilly, Emma Reis, David Niehaus, Trent Rissover,?and the rest of the MICRO2 study team at The Christ Hospital Health Network on scheduling their first patient in the MICRO2 trial! Currently serving as the Medical Director of the Women's Heart Center at The Christ Hospital Health Network, Dr. Odayme Quesada returns to MICRO2 after making significant contributions in the MICRO trial, the pilot study prior to MICRO2 which was the first in history to explore MCG's role in diagnosing coronary microvascular dysfunction (CMD). On the results from MICRO, Dr. Quesada commented, "This pilot data demonstrated MCG's ability to detect CMD in patients with ANOCA [angina with non-obstructive coronary arteries] using a 90-second non-invasive scan.... If this early data is accurate, MCG holds tremendous potential for the diagnosis of CMD in patients with ANOCA." The ongoing MICRO2 trial was designed and powered to validate the results from MICRO. Our team couldn't be happier to partner with?Dr. Quesada?and the rest of her team in working to make the diagnosis of CMD a simple, fast, and accessible process! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

ICYMI: Recently Willa Bluestone and Eddie Pauline, MBA, OhioCED hosted Representative Adam Mathews at the CardioFlux Imaging Institute with Genetesis. They were able to experience the ease and comfortability of CardioFlux Imaging. They received a full cardio scan and report in under 3 minutes! Huge thanks to our amazing Ohio Life Sciences companies like Genetesis for developing life-changing technology. We are grateful for our elected officials who are supporting innovation! #OhioLifeSciences #innovation #advocacy ?

In about 3 minutes, I had a full cardio scan and report in hand...amazing and disruptive life science technology...grateful for our elected officials like Rep.?Adam Mathews ?who are curious to learn more about the life-changing products that?Ohio Life Sciences companies like?Genetesis?are developing all over this state! Amazing work Peeyush Shrivastava Ryan Yoo ??Vineet Erasala Manny Setegn

Cheers to?PI Dr. Dany Jacob, Dana King, Eric Burgett, Hall Jamie,?and the rest of the MICRO2 study team at Saint Luke's Health System on enrolling their first MICRO2 patient! Prior to the initiation of the MICRO2 trial, the recently published MICRO trial demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) in the space of a 90-second, no-contact scan - a first-of-its-kind exploration in what is now six decades of research into MCG. In contrast, the current gold standard for diagnosis is invasive coronary functional angiography, an option which remains practically out-of-reach for a majority of patients who likely suffer from CMD today. Worse still, clinician recognition of CMD and its impact on long-term outcomes remains low, perhaps due in part to the lack of simple, highly accessible options for diagnosis today. We’re excited to partner with clinicians, like Dr. Jacob and the rest of his team, who are actively working to address this unmet need! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

We're excited to continue our recent stream of announcements with the formal publication of results from the MICRO trial! These results represent the first time MCG has been explored for diagnostic use in patients with potential coronary microvascular dysfunction (CMD) and demonstrate MCG's ability to diagnose CMD in a single 90-second, zero-contact scan. "Our explorations thus far into CMD are a symbol of our commitment to demonstrating MCG's utility across the entire spectrum of ischemic heart disease. It's also clear that [...] the need for a fast functional assessment ischemia is perhaps even more important than before," says Dr. Robert Takla, MD, MBA, FACEP, Chief Medical Officer at Genetesis. On the heels of MICRO, Genetesis has already initiated its pivotal MICRO2 trial, powered to validate the findings from MICRO and intended to be FDA-facing in support of a De Novo submission next year. Read the full announcement here:?https://lnkd.in/gDQFhWem

Kudos to PI Dr. Khaled Ziada, along with Rachel Landis, Kelly Norris, Douglas Eckley, Danielle Kellner, Stephanie Stoianoff, Loretta Winstead, Mark Majchszak, Meghan Khebouz, and the entire MICRO2 study team at Cleveland Clinic for enrolling their first patient in the MICRO2 study! Dr. Ziada's first enrollments come on the heels of the formal publication of results from the pilot MICRO trial, where early data demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) with a simple 90-second, zero-contact scan. Dr. Ziada's team was a key contributor to the success of MICRO and now officially kickstarts their contribution to MICRO2, primarily designed to validate these results in a larger cohort of patients. We're thrilled by the opportunity to collaborate with Dr. Ziada and his colleagues as we further important research in both CMD and MCG together! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congratulations to?PI Dr. Edouard Daher M.D., FACC, Viviane Kazan, M.D.,?and the rest of the MICRO2 study team, including Dr. Robert Takla, MD, MBA, FACEP, Dr. Antonious Attallah, MD, FACC, Dr. Ahiwuala and Nader Abdullah at Ascension St. John on enrolling their first MICRO2 patient! This pivotal FDA-facing study aims to validate CardioFlux MCG’s diagnostic ability to detect myocardial ischemia caused by underlying coronary microvascular dysfunction (CMD). Unfortunately, the current standard of care largely fails CMD patients today, many of whom are misdiagnosed or incorrectly told that their symptoms are benign. These patients are predominantly women. We’re excited to partner with?Dr. Daher?and the rest of his team in solving this critical gap in cardiac care! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

We're thrilled to announce the launch of our groundbreaking clinical trial, MICRO2, which aims to validate early evidence demonstrating MCG’s ability to aid in the noninvasive diagnosis of Coronary Microvascular Dysfunction. Learn more in our press release.